Intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis

被引:0
|
作者
Maruyama, M
Nagahama, T
Yuasa, Y
机构
[1] Tokyo Metropolitan Ohkubo Hosp, Dept Surg, Tokyo, Japan
[2] Tokyo Med & Dent Univ, Dept Hyg, Tokyo, Japan
关键词
CPT-11; liver metastasis; intraperitoneal chemotherapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: CPT-11 is an effective antitumor agent for gastrointestinal malignancy, but the optimum route of administration is unclear. Methods: Intraperitoneal administration of this agent was compared with intravenous administration in mouse models for peritoneal seeding and liver metastasis. The peritoneal seeding model and liver metastasis model were respectively established by inoculation of colon 26 tumor cells into the peritoneal cavity and spleen of female BALB/c mise. CPT-11 (40mg/kg) was injected intraperitoneally or intravenously on days 2 and 5 after inoculation of tumor cells. Results: Intraperitoneal administration of CPT-11 was significantly more effective than intravenous administration for control of both peritoneal seeding and liver metastasis. Conclusion: Intraperitoneal administration of CPT-11 may be a more efficient form of adjuvant chemotherapy for prevention of both peritoneal seeding and liver metastasis in patients with gastrointestinal cancer.
引用
收藏
页码:4187 / 4191
页数:5
相关论文
共 50 条
  • [31] Combination Therapy of Intraperitoneal Rapamycin and Convection-Enhanced Delivery of Nanoliposomal CPT-11 in Rodent Orthotopic Brain Tumor Xenografts
    Mendiburu-Elicabe, Marina
    Gil-Ranedo, Jon
    CURRENT CANCER DRUG TARGETS, 2015, 15 (04) : 352 - 362
  • [32] Successful treatment of duodenal adenocarcinoma with multiple liver metastases by S-1 + irinotecan (CPT-11)
    Yamasaki T.
    Nebiki H.
    Sasaki E.
    Kurai O.
    Clinical Journal of Gastroenterology, 2009, 2 (4) : 287 - 290
  • [33] Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) plus CPT-11 in patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) following treatment with fluoropyrimidine, CPT-11, and oxaliplatin (L-OHP) chemotherapy: WJOG6510G
    Sakai, Daisuke
    Taniguchi, Hiroya
    Tamura, Takao
    Sugimoto, Naotoshi
    Esaki, Taito
    Okuda, Hiroyuki
    Matsumoto, Toshihiko
    Yamazaki, Kentaro
    Denda, Tadamichi
    Yamaguchi, Kensei
    Tsuda, Takashi
    Hosokawa, Ayumu
    Makiyama, Akilaka
    Toblmatsu, Kazutoshi
    Goda, Fuminori
    Otsu, Satoshi
    Kishimoto, Junil
    Boku, Narikazu
    Nakamura, Shinichiro
    Hyodo, Ichinosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G
    Sugimoto, Naotoshi
    Sakai, Daisuke
    Tamura, Takao
    Hara, Hiroki
    Nishina, Tomohiro
    Esaki, Taito
    Okuda, Hiroyuki
    Denda, Tadamichi
    Tsuda, Masahiro
    Satoh, Taroh
    Makiyama, Akitaka
    Yamazaki, Kentaro
    Kuramochi, Hidekazu
    Hosokawa, Ayumu
    Tsuda, Takashi
    Taniguchi, Hiroya
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [35] Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11)
    Potter, PM
    Pawlik, CA
    Morton, CL
    Naeve, CW
    Danks, MK
    CANCER RESEARCH, 1998, 58 (12) : 2646 - 2651
  • [36] Efficacy analyses of a randomized phase III clinical trial of combined therapy with CPT-11/CDDP versus CPT-11 alone in patients with advanced or recurrent gastric cancer refractory to prior S-1 chemotherapy
    Inagaki, Hitoshi
    Nishikawa, Kazuhiro
    Fujitani, Kazumasa
    Sugimoto, Naotoshi
    Shigematsu, Tadashi
    Ishiguro, Tohru
    Tsuburaya, Akira
    Nakamura, Masato
    Nashimoto, Atsushi
    Yamane, Takao
    Yamada, Makoto
    Imano, Motohiro
    Iijima, Shohei
    Oka, Yoshio
    Kataoka, Masato
    Hironaka, Shuichi
    Andoh, Hideaki
    Morita, Satoshi
    Sakamoto, Junichi
    Tsujinaka, Toshimasa
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [37] A RANDOMISED PHASE III CLINICAL TRIAL OF COMBINED THERAPY WITH CPT-11/CDDP VERSUS CPT-11 ALONE IN PATIENTS WITH ADVANCED OR RECURRENT GASTRIC CANCER RESISTANT TO S-1(TRICS STUDY): SAFETY ANALYSIS
    Hasegawa, H.
    Nishikawa, K.
    Inagaki, H.
    Akamaru, S.
    Tokunaga, S.
    Takagi, M.
    Tamura, S.
    Morita, S.
    Sakamoto, J.
    Tsujinaka, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 230 - 230
  • [38] Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2
    Humerickhouse, R
    Lohrbach, K
    Li, L
    Bosron, WF
    Dolan, ME
    CANCER RESEARCH, 2000, 60 (05) : 1189 - 1192
  • [39] Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase
    Wierdl, M
    Morton, CL
    Weeks, JK
    Danks, MK
    Harris, LC
    Potter, PM
    CANCER RESEARCH, 2001, 61 (13) : 5078 - 5082
  • [40] Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis
    Ishigami, H.
    Kitayama, J.
    Kaisaki, S.
    Hidemura, A.
    Kato, M.
    Otani, K.
    Kamei, T.
    Soma, D.
    Miyato, H.
    Nagawa, H.
    EJC SUPPLEMENTS, 2009, 7 (02): : 368 - 368